Applied Biosystems and GeneGo Collaborate to Advance Understanding of Tissue Gene Expression; GeneGo Integrates Applied Biosystems Tissue Gene Expression Database Into Its MetaCore(TM) Data Mining Platform.

FOSTER CITY, Calif. & St. Joseph, Mich. -- Applied Biosystems (NYSE:ABI), an Applera Corporation business, and GeneGo, Inc., a leading provider of software and databases for systems biology, today announced a collaboration designed to enhance researchers' ability to study differential gene expression in biological pathways. As part of the agreement, GeneGo has integrated the Applied Biosystems Tissue Gene Expression Database into its MetaCore(TM) data mining platform.

The companies said the integration of this proprietary data into MetaCore is expected to save researchers both time and costs that would otherwise be required to generate comparable comprehensive and high-quality curated data. The combined solution facilitates microarray experiments, such as comparing gene expression changes in normal versus diseased or treated human tissues.

The Tissue Expression Database, created using the Applied Biosystems Expression Array System and Human Genome Survey Microarray, is a proprietary dataset of genome-wide gene expression values from 31 normal tissues and a Universal Human Reference RNA. This extensive dataset can serve as a baseline reference for microarray results and a source for identifying tissue-specific genes. Applying highly sensitive chemiluminescent technology, advanced bioinformatics, and a combination of public and proprietary data, the Applied Biosystems Expression Array System can detect more genes with greater specificity and sensitivity than other commercially available microarray platforms.

"Organ, tissue and cell type specificity are extremely important in human and other mammalian gene expression analysis," said Tatiana Nikolskaya, chief scientific officer and founder of GeneGo. "The Applied Biosystems Tissue Expression Database is high quality, standardized and very well annotated data. We have integrated it as a tissue expression filter in our latest product release to replace the publicly available, but less consistent, UniGene data, and look forward to collaborating on additional ways to leverage our complementary solutions."

MetaCore is used by major pharmaceutical companies and numerous academic institutions for target selection and validation, identification of biomarkers for disease states and toxicology analysis. By enabling the visualization and analysis of complex experimental data in an integrated manner, the solution is designed for systems biology applications. MetaCore is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry and is designed for analysis of gene expression, genetic variations, and proteomic and metabolite profiles. Such integrated analysis helps accelerate the drug discovery and development process and also helps eliminate drug candidates that will have harmful side effects or interactions before they are tested in humans.

"GeneGo has a strong track record of integrating best-of-class technologies and data into its software platform to support emerging systems biology applications," said Carl Hull, vice president for the sequence detection system and microarray business units of Applied Biosystems. "This collaboration represents a mutually beneficial way to support our respective customers in their endeavors to turn their valuable data into meaningful information in the drug discovery and development process."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.

MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of over $1.9 billion during fiscal 2006. The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers. Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera Genomics is also discovering and validating therapeutic targets, and it is seeking to develop therapeutic products based on these discovered targets through strategic partnerships. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should, "planned," and "expect," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Copyright(C) 2006. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.